Results 61 to 70 of about 21,762 (295)

Article III: Some Building Blocks [PDF]

, 1998
Ye
Pearson, Graham S.
core  

The light chain of tetanus toxin inhibits calcium-dependent vasopressin release from permeabilized nerve endings [PDF]

, 1992
The effects of tetanus toxin and its light and heavy chain subunits on vasopressin release were investigated in digitonin-permeabilized neurosecretory nerve terminals isolated from the neural lobe of the rat pituitary gland.
Ahnert-Hilger, G., Dayanithi, G., Gratzl, Manfred, Lnk, H., Nordmann, J. J., Weller, U.   +5 more
core   +1 more source

The Spectrum of Abnormal Tongue Movements: Review of Phenomenology, Etiology, and Differential Diagnosis

Movement Disorders Clinical Practice, EarlyView.
ABSTRACT Background Classifying abnormal tongue movements is challenging due to their varied presentations and limited visibility compared to other body parts. Accurate identification of the phenomenology guides physical examination and can point to specific diagnoses.
Nathaniel Bendahan, Seyed‐Mohammad Fereshtehnejad, Christos Ganos, Emily Swinkin, Anthony E. Lang   +4 more
wiley   +1 more source

Botulinum toxin type A in chronic neuropathic pain in refractory leprosy

Arquivos de Neuro-Psiquiatria
Neuropathic pain is a chronic syndrome that is difficult to treat and often affects patients with leprosy. Recommended treatment includes the the use of analgesic drugs, codeine, tricyclic antidepressants, neuroleptics, anticonvulsants and thalidomide ...
Emanuel de Jesus Soares de Sousa, Gustavo Celeira de Sousa, Vitor Ferreira Baia, Danusa Neves Somensi, Marília Brasil Xavier   +4 more
doaj   +1 more source

Cluster of Botulism among dutch tourists in Turkey, june 2008 [PDF]

, 2010
In June 2008, three Dutch tourists participating in a mini-cruise in Turkey needed urgent repatriation for antitoxin treatment because of symptoms of botulism.
Ouwerkerk, M., van, Roest, H.I.J., Swaan, C.M.   +2 more
core   +1 more source

DaxibotulinumtoxinA for Injection in Adults with Cervical Dystonia: Clinical Insights from a Real‐World Early Experience Program

Movement Disorders Clinical Practice, EarlyView.
ABSTRACT Background DaxibotulinumtoxinA for injection (DAXI), a novel botulinum toxin (BoNT) formulated with a custom‐engineered peptide, was recently approved for treating cervical dystonia (CD). DAXI demonstrated a long duration of symptom relief in Phase 3 trials. Objective To report findings from PrevU, an early experience, real‐world observational
Laxman Bahroo, Aaron Ellenbogen, Robert A. Hauser, Han S. Lee, Peter McAllister, Atul T. Patel, Rashid Kazerooni, Todd M. Gross, Julia Sparrow, Conor J. Gallagher, David A. Hollander   +10 more
wiley   +1 more source

Voice and Speech in Atypical Parkinsonian Disorders

Movement Disorders Clinical Practice, EarlyView.
Background Motor speech disorders are early, common, and functionally limiting features of atypical parkinsonian disorders (APDs) such as progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and multiple system atrophy (MSA). These impairments are underrecognized and undertreated in neurology clinics.
Federico Rodriguez‐Porcel, Farwa Ali, Michiko Bruno, Heather Davis Cuevas, Rohit Dhall, Kylie Dunne‐Platero, Lawrence I. Golbe, Ihtsham Haq, Nicole Herndon, Lawrence S. Honig, Kyurim Kang, Sarah Kremen, Guillaume Lamotte, Nikolaus R. McFarland, Michela Mir, Leila Montaser‐Kouhsari, Alexander Pantelyat, Joel Page, Hylan Pickett, Laura Purcell Verdun, Kelly Richardson, Jessica Shurer, Michelle Troche, Rene L. Utianski, Katya Villarreal‐Cavazos, Tuhin Virmani, Anne‐Marie Wills, as the Diagnosis and Treatment Working Group, CurePSP Center of Care (CoC) Network, Farwa Ali, Michiko Bruno, Timothy Chang, Rohit Dhall, Kimiko Domoto‐Reilly, Lawrence I. Golbe, Ihtsham Haq, Lawrence S. Honig, Sarah Kremen, Guillaume Lamotte, Zoltan Mari, Nikolaus R. McFarland, Leila Montaser‐Kouhsari, Alexander Pantelyat, Federico Rodriguez‐Porcel, Junaid Siddiqui, Jessica Shurer, Christopher Spears, Tuhin Virmani, Anne‐Marie Wills   +48 more
wiley   +1 more source

Challenging the Clostridium botulinum toxin type A (BoNT/A) with a selection of microorganisms by culture methods and extended storage of used vials to assess the loss of sterility [PDF]

, 2015
In 2002, botulinum toxin type A (BoNT/A) was approved by the US Food and Drug Administration (FDA) for cosmetic use. However, there may be procedural differences between the ways in which a clinician handles, applies and stores the product compared to ...
Crean, Stjohn, Dennison, Sarah Rachel, Morton, Leslie Hugh Glyn, Singhrao, Simarjit Kaur, Turner, Martin   +4 more
core  

Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H. [PDF]

, 2016
BackgroundOnly Clostridium botulinum strain IBCA10-7060 produces the recently described novel botulinum neurotoxin type H (BoNT/H). BoNT/H (N-terminal two-thirds most homologous to BoNT/F and C-terminal one-third most homologous to BoNT/A) requires ...
Arnon, Stephen S, Barash, Jason R, Conrad, Fraser, Fan, Yongfeng, Lou, Jianlong, Marks, James D   +5 more
core   +1 more source

Psychiatric Comorbidity, Tic Severity and Quality of Life in Adults with Tourette's Syndrome

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Psychiatric comorbidities are common in adults with Tourette's Syndrome (TS), and appear to influence both tic severity and quality of life (QOL). Objective To assess the association between psychiatric comorbidities, tic severity and QOL in TS.
Andreas Hartmann, Christelle Nilles, Yulia Worbe, Davide Martino, Naoual Serari, Catherine Deans, Isabella Davenport, Julian Fletcher, Emmanuel Roze, Tamara Pringsheim   +9 more
wiley   +1 more source